

Lung Cancer Treatment

Reference Number: F4585
Date of Response: 5th May 2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Request and Royal Devon and Exeter NHS Foundation Trust Response

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

- Afatinib: **0 patients**
- Alectinib **6 patients**
- Atezolizumab monotherapy: **0 Patients**
- Atezolizumab in combination: **<5 Patients**
- Bevacizumab: **<5 Patients**
- Brigatinib: **0 patients**
- Capmatenib: **0 patients**
- Ceritinib: **0 patients**
- Crizotinib: **<5 Patients**
- Dacomitinib: **0 patients**
- Dabrafenib with Trametinib: **<5 Patients**
- Docetaxel monotherapy: **<5 Patients**
- Durvalumab: **0 patients**
- Erlotinib: **<5 Patients**
- Gefitinib: **0 patients**
- Gemcitabine: **<5 Patients**
- Nintedanib with Docetaxel: **<5 Patients**

- Nivolumab: **0 patients**
- Osimertinib: **13 Patients**
- Paclitaxel: **<5 Patients**
- Pembrolizumab monotherapy: **24 Patients**
- Pembrolizumab in combination: **7 Patients**
- Pemetrexed with Carboplatin/Cisplatin: **<5 Patients**
- Tepotinib: **0 patients**
- Vinorelbine with Cisplatin/Carboplatin: **0 patients**
- Any other SACT: **<5 Patients**
- Palliative care only: **11 Patients**

In accordance with section 40 (2) of the Freedom of Information Act 2000, We are unable to provide the figures for the following treatments:

- **Atezolizumab in combination**
- **Bevacizumab**
- **Crizotinib**
- **Dabrafenib with Trametinib**
- **Docetaxel monotherapy**
- **Erlotinib**
- **Gemcitabine**
- **Nintedanib with Docetaxel**
- **Paclitaxel**
- **Pemetrexed with Carboplatin/Cisplatin**
- **Any other SACT**

We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated using the above products is less than five. Releasing this data could risk the identification of these patients. This would breach Caldicott principles and all principles of the Data Protection Act 1998.

Section 40(2) of the FOIA states that information is exempt from disclosure if it constitutes the personal data of a third party and its disclosure under the FOIA would breach any of the data protection principles or section 10 of the Data Protection Act 1998

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode

districts, CCG's providers and Trusts may allow identification of patients and should not be published.